Trial of 6% HES130/0.4

NCT01010022 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypovolemia
Hemorrhage

Interventions

DRUG: 6% hydroxyethyl starch 130/0.4
DRUG: 6% hydroxyethyl starch 70/0.5 (Salinhes®)

Sponsor

Fresenius Kabi Japan